PRSS3 and breast carcinoma: It has been shown, for example, that mesotrypsin is upregulated in T4‐2 breast cancer cells and that knockdown of mesotrypsin attenuates the malignant phenotype of the cells, while treatment with recombinant purified mesotrypsin enhances it [10].